Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 7/20 | 0.37 |
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16398939 | 1.00 | NFE2L2 (0.39) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL31622837 | 1.00 | NFE2L2 (0.39) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL16399364 | 0.84 | NFE2L2 (0.39) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL16399363 | 0.84 | NFE2L2 (0.39) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL17969137 | 0.84 | NFE2L2 (0.51) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL17969139 | 0.84 | NFE2L2 (0.51) | NFE2L2PTGS1PTGS2HTR2AHTR2C | |
| SCHEMBL16403154 | 0.81 | NFE2L2 (0.42) | NFE2L2 | |
| SCHEMBL16403155 | 0.81 | NFE2L2 (0.42) | NFE2L2 | |
| SCHEMBL31622876 | 0.81 | NFE2L2 (0.42) | NFE2L2 | |
| SCHEMBL17969097 | 0.81 | ERBB2 (0.47) | NFE2L2PTGS1PTGS2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | claimed |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-11 | — | — | US | claimed |
| EP-3022199-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2016-05-25 | — | — | EP | claimed |
| WO-2015008872-A1 | CYANOTRIAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-01-22 | — | — | WO | claimed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | NFE2L2 1380/4885PTGS1 2094/4885PTGS2 2928/4885 |
| US-20160229816-A1 | CYANOTRIAZOLE COMPOUNDS | CS, PC, ACAT1 | NFE2L2 1380/4885PTGS1 2094/4885PTGS2 2928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.